Jump to main content
Jump to site search

Issue 13, 2007
Previous Article Next Article

Ruthenium complexes can target determinants of tumour malignancy

Author affiliations

Abstract

Metastases are more decisive for tumour prognosis than primary lesions, because of their multiple locations, low accessibility to surgery and/or radiotherapy, and generally poor responsiveness to chemotherapy. The metastasis should therefore be the primary target for drug therapy. Among ruthenium complexes, NAMI-A is a leading compound that shows selective effects for solid tumour metastases related to a mechanism of action involving the inhibition of the processes of tumour invasiveness. NAMI-A opens an avenue to new perspectives in cancer chemotherapy. This includes novel compounds directed at targets selectively expressed by tumour metastases, thus reducing the typical side effects of the current metal-based drugs that are active via their unselective DNA interaction.

Graphical abstract: Ruthenium complexes can target determinants of tumour malignancy

Back to tab navigation

Publication details

The article was received on 05 Dec 2006, accepted on 12 Feb 2007 and first published on 28 Feb 2007


Article type: Perspective
DOI: 10.1039/B617769G
Citation: Dalton Trans., 2007,0, 1267-1272
  •   Request permissions

    Ruthenium complexes can target determinants of tumour malignancy

    A. Bergamo and G. Sava, Dalton Trans., 2007, 0, 1267
    DOI: 10.1039/B617769G

Search articles by author

Spotlight

Advertisements